There are more treatments today than ever before to help people with ongoing conditions manage their physical symptoms. But even with these medical advances, a diagnosis of myelodysplastic syndromes ...

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r ...

SugarMDs is thrilled to announce the highly anticipated return of its Advanced Glucose Support formula, available for purchase starting February 12th. With an improved formulation and an ...

The study, which pulled self-reported data from online bulletin boards across the US, Canada, and the United Kingdom in 2020, found that the degree of burden varied based on patient disease stage, ...

MDS can cause fatigue and reduce your appetite. Here are some nutrient-dense recipes that can boost your energy, support your immune function, and help you better tolerate treatments. Myelodysplastic ...

Median overall survival of 13.4 months in 32 r/r MDS patients treated with bexmarilimab + azacitidine ORR of 63% and 72% observed in patients with r/r MDS (n=32) and frontline MDS patients (n=18), ...